Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2953-2966

  Bays, Harold ^a   Sapre, Aditi ^b   Taggart, William ^b   Liu, Ji ^b   Capece, Rachel ^b   Tershakovec, Andrew ^b  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Ezetimibe; Ezetimibe simvastatin combination; Hypercholesterolemia; Safety; Simvastatin; Statin

Indexed keywords

EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; PLACEBO; SIMVASTATIN;

ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD DISEASE; BREAST DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HEART DISEASE; HEPATOBILIARY DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOPATHOLOGY; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LIVER TOXICITY; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MONOTHERAPY; MUSCULOSKELETAL DISEASE; MYOPATHY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHABDOMYOLYSIS; SKIN DISEASE; THORAX DISEASE; TREATMENT DURATION; URINARY TRACT DISEASE; VASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANTICHOLESTEREMIC AGENTS; AZETIDINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SIMVASTATIN; TIME FACTORS;

EID: 55549103720     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802365094     Document Type: Article

References (28)

1. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003;24:729-41
2. van Heek M, Farley C, Compton DS, et al. Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats. Br J Pharmacol 2003; 138:1459-64
3. van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur J Pharmacol 2001;415: 79-84
4. Ballantyne CM. Role of selective cholesterol absorption inhibition in the management of dyslipidemia. Curr Atheroscler Rep 2004;6:52-9
5. Sudhop T, Lutjohann D, Kodal A, et al. Inhibition of Intestinal Cholesterol Absorption by Ezetimibe in Humans. Circulation 2002;106:1943-8
6. Moghadasian M. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Life Sci 1999;65:1329-37
7. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511
8. Stein EA. An investigative look: selective cholesterol absorption inhibitors-embarking on a new standard of care. Am J Managed Care 2002;8:36-9
9. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91:418-24
10. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-34
11. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409-15
12. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24:717-28
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
14. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335:1001-9
15. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of Cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-57
16. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
18. Bays H. Statin Safety: An Overview and Assessment of the Data - 2005 [National Lipid Association (NLA) Statin Safety Supplement]. Am J Cardiol 2006;97(Suppl):6-26C
19. Masana L, Mata P, Gagne C, et al. Long-term safety and tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther 2005;27:174-84
20. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety an tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004;58:653-8
21. Ose L, Johnson-Levonas A, Reyes R, et al. A multi-centre, randomized, double-blind 14 week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract 2007; 61:1469-80
22. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;269:3015-23
23. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 2004;79:620-9
24. Grundy SM, Cleeman J, I, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39
25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502
26. Bays H. Ezetimibe. Expert Opin Invest Drugs 2002; 11:1587-604
27. Ose L, Bays H, Fraser N, et al. Efficacy and safety of ezetimibe/ simvastatin combination tablet compared with simvastatin alone in patients with primary hypercholesterolemia. Atherosclerosis 2004;5:140-1
28. Rossebo A, Pedersen T, Allen C, et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am J Cardiol 2007;99:970-3